A Phase II Trial of 5-Fluorouracil, Leucovorin, and Interferon Alpha 2A (IFN-&agr; 2a) in Metastatic Pancreatic CarcinomaA Penn Cancer Clinical Trials Group (PCCTG) Trial
作者:
Alice David,
David Vaughn,
Christopher Holroyde,
Barbara Armstead,
Daniel Haller,
期刊:
American Journal of Clinical Oncology: Cancer Clinical Trials
(OVID Available online 2000)
卷期:
Volume 23,
issue 1
页码: 37-39
ISSN:0277-3732
年代: 2000
出版商: OVID
关键词: Metastatic pancreatic carcinoma;Biochemical modulation;Chemotherapy.
数据来源: OVID
摘要:
A phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil (5-FU), leucovorin, and inteferon &agr;-2a in metastatic pancreatic carcinoma. Twenty-three patients were entered in this study. Four patients withdrew before receiving treatment and one patient was nonevaluable for response because of treatment-related toxicity. The most common significant toxicity was nausea and vomiting. Treatment-related hospitalization was significant. Of 18 evaluable patients, 4 maintained stable disease and 14 had disease progression. None had an objective clinical response. We conclude that this biochemically modulated 5-FU regimen is ineffective treatment for advanced pancreatic carcinoma, with significant toxicity even in highly selected patients with an ambulatory performance status.
返 回